Literature DB >> 2886437

Renal tolerance of cefpirome (HR 810), a new cephalosporin antibiotic.

M Verho, L Maass, V Malerczyk, H Grötsch.   

Abstract

An open study was carried out in ten healthy, male volunteers in order to investigate the renal tolerance of cefpirome (HR 810), a new cephalosporin antibiotic. Subjects received a single dose of 1.0 g of cefpirome and then repeated doses of 1.0 g of cefpirome twice daily for five days. Urine was collected in several fractions during the study and the urine excretion, excretions of creatinine, N-acetyl-beta-D-glucosaminidase, gamma glutamyltransferase, alanine aminopeptidase and lactate dehydrogenase were calculated in 12-hour fractions. Serum creatinine (using an enzymatic method), beta 2-microglobulin concentrations and creatinine clearance were also determined. Based on the findings of these renal enzymes, renal tolerance was good. This was also confirmed by creatinine clearance calculations and follow-up of serum beta 2-microglobulin levels. Cefpirome showed good renal tolerance without any signs of nephrotoxicity in this study with the methods used.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2886437     DOI: 10.1007/bf01646054

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  Letter: Reversible acute renal failure after cephalothin.

Authors:  J E Engle; J Drago; B Carlin; A C Schoolwerth
Journal:  Ann Intern Med       Date:  1975-08       Impact factor: 25.391

2.  Acute renal failure during cephalothin therapy.

Authors:  J R Burton; N S Lichtenstein; R B Colvin; N E Hyslop
Journal:  JAMA       Date:  1974-08-05       Impact factor: 56.272

3.  Serum 2 -microglobulin in renal disease.

Authors:  L Wibell; P E Evrin; I Berggård
Journal:  Nephron       Date:  1973       Impact factor: 2.847

4.  The serum levels and urinary excretion of 2 -microglobulin in apparently healthy subjects.

Authors:  P E Evrin; L Wibell
Journal:  Scand J Clin Lab Invest       Date:  1972-02       Impact factor: 1.713

5.  The excretion of N-acetyl-beta-glucosaminidase and beta-galactosidase by patients with renal disease.

Authors:  N Dance; R G Price; W R Cattell; J Lansdell; B Richards
Journal:  Clin Chim Acta       Date:  1970-01       Impact factor: 3.786

Review 6.  Urinary enzymes, nephrotoxicity and renal disease.

Authors:  R G Price
Journal:  Toxicology       Date:  1982       Impact factor: 4.221

7.  Mechanisms of cephalosporin nephrotoxicity: a comparison of cephaloridine and cephaloglycin.

Authors:  B M Tune; D Fravert
Journal:  Kidney Int       Date:  1980-11       Impact factor: 10.612

8.  Investigations on the potential nephrotoxicity of cefazedone and gentamicin and of their combination, in comparison with the combination of cefazolin and cephalothin with gentamicin.

Authors:  A W Mondorf
Journal:  Arzneimittelforschung       Date:  1979

9.  HR 810, a new parenteral cephalosporin with a broad antibacterial spectrum.

Authors:  G Seibert; N Klesel; M Limbert; E Schrinner; K Seeger; I Winkler; R Lattrell; J Blumbach; W Dürckheimer; K Fleischmann
Journal:  Arzneimittelforschung       Date:  1983

10.  Antibiotic nephrotoxicity.

Authors:  J P Morin; J P Fillastre; B Olier
Journal:  Chemioterapia       Date:  1984-02
View more
  2 in total

Review 1.  A review of the adverse events profile of cefpirome.

Authors:  E Rubinstein; R Labs; A Reeves
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

Review 2.  Cefpirome clinical pharmacokinetics.

Authors:  L C Strenkoski; D E Nix
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.